Results 111 to 120 of about 750,934 (136)

Glycyrrhiza uralensis polysaccharides as a DC-based Vaccine Adjuvant: Enhanced Immunotherapy Combined with PD-1 Blockade

Aili P, Cai S, Chen B, Aobulikasimu N, Han L, Aipire A.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

PD-1 and Autoimmunity

Critical Reviews™ in Immunology, 2011
An initiating T cell response requires both costimulatory signaling and T cell receptor/MHC binding. The immune system balances positive and negative costimulatory signal pathways to activate and deactivate T cells. This review focuses primarily on PD-1 and its ligands, which form a crucial inhibitory costimulatory pathway for maintaining peripheral ...
Shimpei, Kasagi, Seiji, Kawano, Shunichi, Kumagai   +2 more
openaire   +2 more sources

Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1)

Preparative Biochemistry & Biotechnology, 2019
Targeting the interaction interface is an effective strategy to obtain programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-L1) nanobody blockers. To validate this strategy, the interaction interface between PD-1 and the PD-L1 extracellular domain were analyzed using Cn3D 4.1. The peptide PD-1125-136 located at the interface of PD-1 was selected as the
Biyan, Wen, Lin, Zhao, Yuchu, Wang, Chuangnan, Qiu, Zhimin, Xu, Kunling, Huang, He, Zhu, Zemin, Li, Huangjin, Li   +8 more
openaire   +2 more sources

PD-1–PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma

Blood, 2008
AbstractProgrammed death-1 (PD-1)–PD-1 ligand (PD-L) signaling system is involved in the functional impairment of T cells such as in chronic viral infection or tumor immune evasion. We examined PD-L expression in lymphoid cell lines and found that they were up-regulated on Hodgkin lymphoma (HL) and several T-cell lymphomas but not on B-cell lymphomas ...
Ryo, Yamamoto, Momoko, Nishikori, Toshio, Kitawaki, Tomomi, Sakai, Masakatsu, Hishizawa, Masaharu, Tashima, Tadakazu, Kondo, Katsuyuki, Ohmori, Masayuki, Kurata, Takamasa, Hayashi, Takashi, Uchiyama   +10 more
openaire   +2 more sources

Targeting PD-1

Science Signaling, 2018
Loss of an E3 ubiquitin ligase that targets PD-1 for degradation leads to inefficient antitumor responses by T cells.
openaire   +1 more source

Molecular Imaging of PD-1 Unveils Unknown Characteristics of PD-1 Itself by Visualizing “PD-1 Microclusters”

Programmed cell death-1 (PD-1) is one of the most famous coinhibitory receptors that are expressed on effector T cells to regulate their function. The PD-1 ligands, PD-L1 and PD-L2, are expressed by various cells throughout the body at steady state and their expression was further regulated within different pathological conditions such as tumor-bearing
Wataru, Nishi, Ei, Wakamatsu, Hiroaki, Machiyama, Ryohei, Matsushima, Yosuke, Yoshida, Tetsushi, Nishikawa, Hiroko, Toyota, Masae, Furuhata, Hitoshi, Nishijima, Arata, Takeuchi, Makoto, Suzuki, Tadashi, Yokosuka   +11 more
openaire   +2 more sources

FBXO38 Drives PD-1 to Destruction

Trends in Immunology, 2019
Aberrant expression of T cell-resident programmed cell death protein-1 (PD-1) is known to promote tumor progression. A recent study (Nature 2018;564:130-135) has now identified the E3 ubiquitin ligase FBXO38 as a crucial regulator of PD-1 protein turnover in T cells, providing a novel mechanism for potential use in cancer immunotherapy.
Taryn M, Serman, Michaela U, Gack
openaire   +2 more sources